Relypsa (RLYP): Veltassa's Path To Preferred Hyperkalemia Treatment - Wedbush

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. AMGN
3. BKNG
4. DOX
5. DUOL
6. ANET
7. XYZ
8. SWKS
9. SPY
10. FISV

Go back to Relypsa (RLYP): Veltassa's Path To Preferred Hyperkalemia Treatment - Wedbush

Relypsa's (RLYP) Veltassa Expected to Benefit from Delay to AstraZeneca's (AZN) ZS-9 - BTIG

June 2, 2016 7:47 AM EDT

BTIG affirms Relypsa (Nasdaq: RLYP) at Buy with a price target of $35 following recent conversations with management.

Analyst Timothy Chiang commented, We recently hosted a Q&A session with Relypsas senior management team to discuss a number of key items including the recent CRL... More

Mizuho Securities Upgrades Relypsa (RLYP) to Neutral; Strengthened Veltassa Launch and Higher Probability of a Takeout

June 1, 2016 6:18 AM EDT

Mizuho Securities upgraded Relypsa, Inc. (NASDAQ: RLYP) from Underperform to Neutral with a price target of $20.00 (from $12.00).

Analyst Irina Koffler commented, "Relypsa's stock is benefiting from a regulatory delay of competitor AZN, which gives Relypsa more time to strengthen its Veltassa launch and explore strategic alternatives. With the recent run-up, we believe shares are fairly valued and upgrade the stock to Neutral from... More